Innovative Biomarker Technology Olink specializes in high-multiplex proteomics with exceptional sensitivity and specificity, enabling clients to identify actionable biomarkers across various disease areas. This positions them as a key partner for research organizations and pharmaceutical companies seeking advanced biomarker discovery solutions.

Expanding Global Presence With established headquarters in Sweden and the US, along with a rapidly growing footprint in Asia, Olink offers opportunities to expand sales efforts in emerging markets. Partnering with regional labs and distributing channels could significantly increase global adoption of their proteomics offerings.

Recent Strategic Partnerships Recent collaborations, such as the partnership with Evotec for translational biomarker discovery, highlight Olink’s ability to align with pharmaceutical and biotech firms. Leveraging these alliances can facilitate new sales channels within drug development and translational research sectors.

Thermo Fisher Acquisition The pending acquisition by Thermo Fisher Scientific for $3.1 billion signals strong industry validation and potential for increased product integration. This agreement opens avenues to target Thermo Fisher’s extensive customer base for bundled solutions and cross-selling opportunities.

Funding and Revenue Growth With revenues estimated between $250M and $500M and recent funding of $117M, Olink demonstrates robust financial health and growth potential. This makes them an attractive candidate for strategic partnerships and long-term sales engagements focused on their expanding product coverage and technological capabilities.